Liu, Xiangjuan <br/><br/>
Irbesartan ameliorates diabetic cardiomyopathy by regulating protein kinase D and ER stress activation in a type 2 diabetes rat model.  [electronic resource] 

 -  Pharmacological research  Mar 2015 
 - 43-51 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1096-1186 
<br/><br/><label>Standard No.: </label>10.1016/j.phrs.2015.01.001  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Biphenyl Compounds--pharmacology<br/>Cardiotonic Agents--pharmacology<br/>Diabetes Mellitus, Experimental--drug therapy<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Diabetic Cardiomyopathies--drug therapy<br/>Endoplasmic Reticulum Stress--drug effects<br/>Irbesartan<br/>Male<br/>Myocardium--pathology<br/>Protein Kinase C--antagonists & inhibitors<br/>Rats, Sprague-Dawley<br/>Tetrazoles--pharmacology